Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death in Europe and the United States (Malvezzi et al Ann Oncol 24(3):792 - 800, 2013). At the time of diagnosis, approximately half of patients with pancreatic adenocarcinoma will have synchronous metastasis. Patients with metastatic pancreatic cancer generally have a median survival of 6 months and a 5-year survival of about 2 - 5 %. The liver is a frequent site of metastasis as pancreatic adenocarcinoma can metastasize to the liver through portal venous or intra-abdominal lymphatic drainage. For example, in a study from Johns Hopkins Hospital, among 838 patients with pancreatic adenocarcinoma who underwent a pancreatectomy, 46 % subsequently developed metachronous liver metastasis. Of note, among those patients with pancreatic cancer metastatic to the liver, 60 % had isolated liver metastasis without extrahepatic recurrence at the time of last follow-up.
| Original language | English (US) |
|---|---|
| Title of host publication | Noncolorectal, Nonneuroendocrine Liver Metastases |
| Subtitle of host publication | Diagnosis and Current Therapies |
| Publisher | Springer International Publishing |
| Pages | 95-109 |
| Number of pages | 15 |
| ISBN (Electronic) | 9783319092935 |
| ISBN (Print) | 9783319092928 |
| DOIs | |
| State | Published - Jan 1 2015 |
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Liver metastases from pancreatic adenocarcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS